Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

NHS spending on drugs fell in 2011

April 4, 2012 Sales and Marketing NHS, cost savings, generic, patent, prescriptions, spend

The NHS in England spent less on its drugs budget last year, bucking the longstanding upward trend. This is because …
News

GSK’s diabetes drug misses goal

April 4, 2012 Research and Development, Sales and Marketing Bydureon, GSK, Victoza, albiglutide, diabetes

GlaxoSmithKline has insisted its new long-acting Type 2 diabetes drug albiglutide remains on course for filing following topline results from …
News

EMG appoints two new senior members

April 4, 2012 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing EMG, Matthew Speers, Steve Turley, UCB

A new chair and vice-chair have been appointed to lead the European Medicines Group (EMG).   EMG is the voice of …
Appointment

Glyn Edwards appointed as chief executive of Summit

April 4, 2012 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Glyn Edwards, summit

Summit, a UK drug discovery company, has appointed Glyn Edwards as its new chief executive. Edwards will take up the …
Appointment

EMA creates new conflict of interest rules

April 4, 2012 Sales and Marketing EMA, Lonngren, conflict of interest

The European Medicines Agency has introduced new rules to tighten up conflicts of interest, and have less reliance on pharma …
News

New Europe-wide approach for the classification of commercially confidential information and personal data in MAAs

April 3, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The Heads of Medicines Agencies(HMA) and the European Medicines Agency (EMA) have adopted a joint guidance document, providing a consistent …
News
Press release

Bayer cancer drug meets Phase III goal

April 3, 2012 Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib

Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
News

Life appoints new digital developer

April 3, 2012 Business Services, Medical Communications, Sales and Marketing Life, Nick Douglas

Life Healthcare Communications has created a new digital developer role, continuing the growth of its digital department.  The firm has …
Appointment

Michael Cola resigns from Shire

April 3, 2012 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Michael Cola, Shire

Michael Cola has resigned as the president of Shire Specialty Pharmaceuticals after seven years at the firm.  “On behalf of …
Appointment

NICE rejects Halaven for breast cancer

April 3, 2012 Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …
News

Universal WorldEvents Marks Anniversary with Increase in Events

April 2, 2012 Sales and Marketing

Universal WorldEvents has marked its first anniversary by revealing a significant increase in the number of events organised by the …
News
Press release

AstraZeneca wins fresh US victory with Seroquel XR

April 2, 2012 Sales and Marketing AZ, AstraZeneca, FDA, Seroquel XR

AstraZeneca is celebrating a US court verdict in its ongoing battle for intellectual property over the extended release version of …
News

Roche to submit Herceptin successor to regulators

April 2, 2012 Research and Development, Sales and Marketing GSK, Herceptin, Roche, Xeloda

Roche has said it will submit its new breast cancer drug trastuzumab for regulatory review in the US and Europe …
News

Roche raises Illumina bid to $6.7 billion

April 2, 2012 Sales and Marketing

Roche has increased its takeover bid for Illumina, with the offer now valuing the company at $6.7 billion.The firm makes …
News

Amylin dismisses BMS acquisition deal

March 30, 2012 Manufacturing and Production, Sales and Marketing Amylin, BMS, Bydureon, diabetes, lilly

Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to reports. Shares in Amylin rose …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026